“How many different cell types are there in the human body? And how do these differences develop? Nobody really knows,” says Professor Stein Aerts from KU Leuven/VIB. But thanks to a new method developed by his team, that may be about to change.
The device that was developed last year to provide wireless measurement of vital signs such as respiration and heartbeat has been downsized and further advanced.
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The conditional approval allows two U.S. sites to enroll up to five total patients. The FDA has also requested that the Company conduct additional device testing and address outstanding questions. Second Sight has 45 days to respond to FDA's requests.
A report, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
A DNA nanorobot is programmed to pick up and sort molecules into predefined regions.
The Laboratory of Hybrid Biomaterials of Tomsk Polytechnic University invites TPU students, including international ones, as well as master students and postgraduates for research collaboration.